

*This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183*

Printed By

# Dr Reddy's Gears For Sputnik Pediatric Shot, Molnupiravir Upside

01 Nov 2021 | **ANALYSIS**

by Anju Ghangurde | @ScripAnjuG | anju.ghangurde@informa.com

## Executive Summary

Dr Reddy's indicates it is close to break-even between "the investment made and what we gained" for Russian COVID-19 vaccine Sputnik V in India, with Sputnik Light, boosters and pediatric shots seen as the new growth drivers. The company's fully vertically integrated operations also puts it in prime position for supplies of antiviral molnupiravir.

## You may also be interested in...

---

### Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Pfizer's mixed Q3; delayed US approval for Janssen/Legend's CAR-T; promising new data in RSV; Dr Reddy's lays out more COVID product plan...

### Merck's Molnupiravir Open License With Medicines Patent Pool May Be Model

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can't...

### Pediatric COVID-19 Vaccine Face-Off Looms As Bharat Biotech Heads For Approval

While Bharat Biotech is close to an accelerated approval of Covaxin in two to 18-year-olds, Zydus Cadila is yet to roll out its COVID-19 vaccine in India. As they head to a face-off in pediatric vaccines, the former faces manufacturing constraints and the latter hesitance over a first of its kind DNA vaccine. Experts speak to *Scrip* on which one stands a better chance of winning.

## Existing Subscriber?

Sign in to continue reading.

SIGN IN

## New to Scrip?

Start a free trial today!

FREE TRIAL



DR REDDY'S PRIMES LIFE CYCLE MANAGEMENT PLANS FOR SPUTNIK

Source: Alamy